BACKGROUND: The demonstration of in vitro cardiolipin reactivity with 2 human immunodeficiency virus (HIV)-specific, broadly neutralizing antibodies (2F5 and 4E10) has prompted reevaluation of autoimmune manifestations in HIV infection. METHODS: We evaluated autoantibodies, particularly anticardiolipin (aCL), in 67 untreated, asymptomatic, HIV-infected individuals with slow progression of HIV disease and their correlation with 2F5-, 4E10-, b12-, and 2G12-like antibodies directed against epitopes involved in broad neutralization, as well as their correlation with immune activation and virological and clinical indicators. Fifty individuals with chronic HIV infection and standard disease progression were control patients. RESULTS: The majority of the study patients with slow progression of HIV disease were men (78%); their median age was 37 years, their median CD4+ cell count was 672 cells/mL, and their median plasma HIV load was 6200 copies/mL. The majority of the control patients were also men (76%), and most (62%) were receiving highly active antiretroviral therapy; their median age was 43 years, their median CD4+ cell count was 202 cells/mL, and their median plasma HIV load was 2265 copies/mL. aCL immunoglobulin G was detected at similar levels in 49% of patients with slow progression of HIV disease and in 58% of control patients. Viral load was positively associated with aCL in both groups (P < .001), independent of CD4+ cell counts. In patients with slow progression of HIV disease, aCL levels were also correlated with plasma HIV load and cell-associated DNA level (r = 0.486 and r = 0.516, respectively; P < .001), with the proportion of activated CD4+ cells, human leukocyte antigen-DR+ cells (r = 0.445; P = or < .001) but not activated CD8+ T cells, and with the level of B cell activation (quantified by soluble CD23; r = 0.354; P = .007). The level of aCL antibodies was associated with the level of antibodies to the membrane proximal region of gp41 (P = .003). CONCLUSION: aCL is frequently detected in HIV-infected patients, regardless of disease stage, and is strongly linked with the level of viral replication, the level of CD4+ T and B cell activation, and the level of antibodies to the membrane proximal external region of gp41, independent of CD4+ cell deficiency.
BACKGROUND: The demonstration of in vitro cardiolipin reactivity with 2 human immunodeficiency virus (HIV)-specific, broadly neutralizing antibodies (2F5 and 4E10) has prompted reevaluation of autoimmune manifestations in HIV infection. METHODS: We evaluated autoantibodies, particularly anticardiolipin (aCL), in 67 untreated, asymptomatic, HIV-infected individuals with slow progression of HIV disease and their correlation with 2F5-, 4E10-, b12-, and 2G12-like antibodies directed against epitopes involved in broad neutralization, as well as their correlation with immune activation and virological and clinical indicators. Fifty individuals with chronic HIV infection and standard disease progression were control patients. RESULTS: The majority of the study patients with slow progression of HIV disease were men (78%); their median age was 37 years, their median CD4+ cell count was 672 cells/mL, and their median plasma HIV load was 6200 copies/mL. The majority of the control patients were also men (76%), and most (62%) were receiving highly active antiretroviral therapy; their median age was 43 years, their median CD4+ cell count was 202 cells/mL, and their median plasma HIV load was 2265 copies/mL. aCL immunoglobulin G was detected at similar levels in 49% of patients with slow progression of HIV disease and in 58% of control patients. Viral load was positively associated with aCL in both groups (P < .001), independent of CD4+ cell counts. In patients with slow progression of HIV disease, aCL levels were also correlated with plasma HIV load and cell-associated DNA level (r = 0.486 and r = 0.516, respectively; P < .001), with the proportion of activated CD4+ cells, human leukocyte antigen-DR+ cells (r = 0.445; P = or < .001) but not activated CD8+ T cells, and with the level of B cell activation (quantified by soluble CD23; r = 0.354; P = .007). The level of aCL antibodies was associated with the level of antibodies to the membrane proximal region of gp41 (P = .003). CONCLUSION: aCL is frequently detected in HIV-infectedpatients, regardless of disease stage, and is strongly linked with the level of viral replication, the level of CD4+ T and B cell activation, and the level of antibodies to the membrane proximal external region of gp41, independent of CD4+ cell deficiency.
Authors: Elin S Gray; Natasha Taylor; Diane Wycuff; Penny L Moore; Georgia D Tomaras; Constantinos Kurt Wibmer; Adrian Puren; Allan DeCamp; Peter B Gilbert; Blake Wood; David C Montefiori; James M Binley; George M Shaw; Barton F Haynes; John R Mascola; Lynn Morris Journal: J Virol Date: 2009-06-24 Impact factor: 5.103
Authors: Maria D I Manunta; Giuseppe Lamorte; Francesca Ferrari; Elena Trombetta; Mario Tirone; Cristiana Bianco; Alessandra Cattaneo; Luigi Santoro; Guido Baselli; Manuela Brasca; Mahnoosh Ostadreza; Elisa Erba; Andrea Gori; Alessandra Bandera; Laura Porretti; Luca V C Valenti; Daniele Prati Journal: Sci Rep Date: 2021-03-01 Impact factor: 4.379
Authors: James J Kobie; Danielle C Alcena; Bo Zheng; Peter Bryk; Jonelle L Mattiacio; Matthew Brewer; Celia Labranche; Faith M Young; Stephen Dewhurst; David C Montefiori; Alexander F Rosenberg; Changyong Feng; Xia Jin; Michael C Keefer; Ignacio Sanz Journal: PLoS One Date: 2012-04-18 Impact factor: 3.240
Authors: Kathryn A K Finton; Kevin Larimore; H Benjamin Larman; Della Friend; Colin Correnti; Peter B Rupert; Stephen J Elledge; Philip D Greenberg; Roland K Strong Journal: PLoS Pathog Date: 2013-09-26 Impact factor: 6.823
Authors: Christopher T Campbell; Sean R Llewellyn; Thorsten Demberg; Thorsten Damberg; Ian L Morgan; Marjorie Robert-Guroff; Jeffrey C Gildersleeve Journal: PLoS One Date: 2013-09-23 Impact factor: 3.240